サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1385400

世界の第三世代EGFR-TKI標的治療薬市場：考察と予測 (2029年まで)

Global Third Generation EGFR-TKI Targeted Therapy Drugs Market Insights, Forecast to 2029

出版日
発行
QYResearch
ページ情報
英文 113 Pages
納期
2～3営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
世界の第三世代EGFR-TKI標的治療薬市場：考察と予測 (2029年まで)
出版日: 2023年11月27日
発行: QYResearch
ページ情報: 英文 113 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは、第三世代EGFR-TKI標的治療薬 (Third Generation EGFR-TKI Targeted Therapy Drugs) 市場について調査しており、市場規模や動向・需要の予測、成長要因および課題の分析、タイプ・用途・企業・地域別の内訳、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 調査対象

  • 第三世代EGFR-TKI標的治療薬の製品概要
  • 市場：タイプ別
    • 世界の第三世代EGFR-TKI標的治療薬の市場規模成長率：タイプ別, 2018 VS 2022 VS 2029
    • Injection
    • Tablet
    • Otherss
  • 市場：用途別
    • 世界の第三世代EGFR-TKI標的治療薬の市場規模成長率：用途別, 2018 VS 2022 VS 2029
    • Lung Cancer Treatment
    • Clinical Research
    • Otherss
  • 前提条件と制限
  • 調査目的
  • 対象期間

第2章 レポート概要

  • 世界の第三世代EGFR-TKI標的治療薬売上予測・予想 2018-2029
  • 世界の第三世代EGFR-TKI標的治療薬の収益：地域別
    • 世界の第三世代EGFR-TKI標的治療薬の収益：地域別: 2018 VS 2022 VS 2029
    • 世界の第三世代EGFR-TKI標的治療薬の収益：地域別 (2018-2023)
    • 世界の第三世代EGFR-TKI標的治療薬の収益：地域別 (2024-2029)
    • 世界の第三世代EGFR-TKI標的治療薬の収益市場シェア 地域別 (2018-2029)
  • 世界の第三世代EGFR-TKI標的治療薬売上予測・予想 2018-2029
  • 世界の第三世代EGFR-TKI標的治療薬の販売：地域別
    • 世界の第三世代EGFR-TKI標的治療薬の販売：地域別: 2018 VS 2022 VS 2029
    • 世界の第三世代EGFR-TKI標的治療薬の販売：地域別 (2018-2023)
    • 世界の第三世代EGFR-TKI標的治療薬の販売：地域別 (2024-2029)
    • 世界の第三世代EGFR-TKI標的治療薬の販売市場シェア 地域別 (2018-2029)
  • 米国・カナダ
  • 欧州
  • 中国
  • アジア（中国を除く）
  • 中東, アフリカ ・ラテンアメリカ

第3章 競合：企業別

  • 世界の第三世代EGFR-TKI標的治療薬の販売：企業別
    • 世界の第三世代EGFR-TKI標的治療薬の販売：企業別 (2018-2023)
    • 世界の第三世代EGFR-TKI標的治療薬の販売市場シェア：企業別 (2018-2023)
    • 世界の上位10・上位5企業： 第三世代EGFR-TKI標的治療薬 in 2022
  • 世界の第三世代EGFR-TKI標的治療薬の収益：企業別
    • 世界の第三世代EGFR-TKI標的治療薬の収益：企業別 (2018-2023)
    • 世界の第三世代EGFR-TKI標的治療薬の収益市場シェア：企業別 (2018-2023)
    • 世界の上位10・上位5企業： 第三世代EGFR-TKI標的治療薬の収益 2022
  • 世界の主要企業 第三世代EGFR-TKI標的治療薬, 業界ランキング, 2021 VS 2022 VS 2023
  • 世界の第三世代EGFR-TKI標的治療薬の販売価格：企業別
  • 競合情勢の分析
    • 企業の市場集中度 (CR5 and HHI)
    • 世界の第三世代EGFR-TKI標的治療薬の市場シェア：企業タイプ別 (Tier 1, Tier 2, and Tier 3)
  • 世界の主要メーカー 第三世代EGFR-TKI標的治療薬, 製造拠点分布と本社
  • 世界の主要メーカー 第三世代EGFR-TKI標的治療薬, 提供製品と用途
  • 世界の主要メーカー 第三世代EGFR-TKI標的治療薬, 業界参入時期
  • M&A, 拡張計画

第4章 市場規模：タイプ別

  • 世界の第三世代EGFR-TKI標的治療薬の販売：タイプ別
    • 世界の第三世代EGFR-TKI標的治療薬の販売実績：タイプ別 (2018-2023)
    • 世界の第三世代EGFR-TKI標的治療薬の販売予測：タイプ別 (2024-2029)
    • 世界の第三世代EGFR-TKI標的治療薬の販売市場シェア：タイプ別 (2018-2029)
  • 世界の第三世代EGFR-TKI標的治療薬 収益：タイプ別
    • 世界の第三世代EGFR-TKI標的治療薬の収益実績：タイプ別 (2018-2023)
    • 世界の第三世代EGFR-TKI標的治療薬の収益予測：タイプ別 (2024-2029)
    • 世界の第三世代EGFR-TKI標的治療薬の収益市場シェア：タイプ別 (2018-2029)
  • 世界の第三世代EGFR-TKI標的治療薬の価格：タイプ別
    • 世界の第三世代EGFR-TKI標的治療薬の価格：タイプ別 (2018-2023)
    • 世界の第三世代EGFR-TKI標的治療薬の価格予測：タイプ別 (2024-2029)

第5章 市場規模：用途別

  • 世界の第三世代EGFR-TKI標的治療薬の販売：用途別
    • 世界の第三世代EGFR-TKI標的治療薬の販売実績：用途別 (2018-2023)
    • 世界の第三世代EGFR-TKI標的治療薬の販売予測：用途別 (2024-2029)
    • 世界の第三世代EGFR-TKI標的治療薬の販売市場シェア：用途別 (2018-2029)
  • 世界の第三世代EGFR-TKI標的治療薬の収益：用途別
    • 世界の第三世代EGFR-TKI標的治療薬の収益実績：用途別 (2018-2023)
    • 世界の第三世代EGFR-TKI標的治療薬の収益予測：用途別 (2024-2029)
    • 世界の第三世代EGFR-TKI標的治療薬の収益市場シェア：用途別 (2018-2029)
  • 世界の第三世代EGFR-TKI標的治療薬の価格：用途別
    • 世界の第三世代EGFR-TKI標的治療薬の価格：用途別 (2018-2023)
    • 世界の第三世代EGFR-TKI標的治療薬の価格予測：用途別 (2024-2029)

第6章 米国・カナダ

  • 米国・カナダ 第三世代EGFR-TKI標的治療薬 市場規模：タイプ別
    • 米国・カナダ 第三世代EGFR-TKI標的治療薬の販売：タイプ別 (2018-2029)
    • 米国・カナダ 第三世代EGFR-TKI標的治療薬 収益：タイプ別 (2018-2029)
  • 米国・カナダ 第三世代EGFR-TKI標的治療薬 市場規模：用途別
    • 米国・カナダ 第三世代EGFR-TKI標的治療薬の販売：用途別 (2018-2029)
    • 米国・カナダ 第三世代EGFR-TKI標的治療薬の収益：用途別 (2018-2029)
  • 米国・カナダ 第三世代EGFR-TKI標的治療薬 市場規模：国別
    • 米国・カナダ 第三世代EGFR-TKI標的治療薬の収益：国別: 2018 VS 2022 VS 2029
    • 米国・カナダ 第三世代EGFR-TKI標的治療薬の販売：国別 (2018-2029)
    • 米国・カナダ 第三世代EGFR-TKI標的治療薬の収益：国別 (2018-2029)
    • US
    • カナダ

第7章 欧州

  • 欧州の第三世代EGFR-TKI標的治療薬 市場規模：タイプ別
    • 欧州の第三世代EGFR-TKI標的治療薬の販売：タイプ別 (2018-2029)
    • 欧州の第三世代EGFR-TKI標的治療薬 収益：タイプ別 (2018-2029)
  • 欧州の第三世代EGFR-TKI標的治療薬 市場規模：用途別
    • 欧州の第三世代EGFR-TKI標的治療薬の販売：用途別 (2018-2029)
    • 欧州の第三世代EGFR-TKI標的治療薬の収益：用途別 (2018-2029)
  • 欧州の第三世代EGFR-TKI標的治療薬 市場規模：国別
    • 欧州の第三世代EGFR-TKI標的治療薬の収益：国別: 2018 VS 2022 VS 2029
    • 欧州の第三世代EGFR-TKI標的治療薬の販売：国別 (2018-2029)
    • 欧州の第三世代EGFR-TKI標的治療薬の収益：国別 (2018-2029)
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • ロシア

第8章 中国

  • 中国の第三世代EGFR-TKI標的治療薬 市場規模
    • 中国の第三世代EGFR-TKI標的治療薬 売上 (2018-2029)
    • 中国の第三世代EGFR-TKI標的治療薬 収益 (2018-2029)
  • 中国の第三世代EGFR-TKI標的治療薬 市場規模：用途別
    • 中国の第三世代EGFR-TKI標的治療薬の販売：用途別 (2018-2029)
    • 中国の第三世代EGFR-TKI標的治療薬の収益：用途別 (2018-2029)

第9章 アジア（中国を除く）

  • アジア地域 第三世代EGFR-TKI標的治療薬 市場規模：タイプ別
    • アジア地域 第三世代EGFR-TKI標的治療薬の販売：タイプ別 (2018-2029)
    • アジア地域 第三世代EGFR-TKI標的治療薬 収益：タイプ別 (2018-2029)
  • アジア地域 第三世代EGFR-TKI標的治療薬 市場規模：用途別
    • アジア地域 第三世代EGFR-TKI標的治療薬の販売：用途別 (2018-2029)
    • アジア地域 第三世代EGFR-TKI標的治療薬の収益：用途別 (2018-2029)
  • アジア地域 第三世代EGFR-TKI標的治療薬の販売：地域別
    • アジア地域 第三世代EGFR-TKI標的治療薬の収益：地域別: 2018 VS 2022 VS 2029
    • アジア地域 第三世代EGFR-TKI標的治療薬の収益：地域別 (2018-2029)
    • アジア地域 第三世代EGFR-TKI標的治療薬の販売：地域別 (2018-2029)
    • 日本
    • 韓国
    • 台湾
    • 東南アジア
    • インド

第10章 中東, アフリカ ・ラテンアメリカ

  • 中東, アフリカ ・ラテンアメリカの第三世代EGFR-TKI標的治療薬 市場規模：タイプ別
    • 中東, アフリカ ・ラテンアメリカの第三世代EGFR-TKI標的治療薬の販売：タイプ別 (2018-2029)
    • 中東, アフリカ ・ラテンアメリカの第三世代EGFR-TKI標的治療薬 収益：タイプ別 (2018-2029)
  • 中東, アフリカ ・ラテンアメリカの第三世代EGFR-TKI標的治療薬 市場規模：用途別
    • 中東, アフリカ ・ラテンアメリカの第三世代EGFR-TKI標的治療薬の販売：用途別 (2018-2029)
    • 中東, アフリカ ・ラテンアメリカの第三世代EGFR-TKI標的治療薬の収益：用途別 (2018-2029)
  • 中東, アフリカ ・ラテンアメリカの第三世代EGFR-TKI標的治療薬の販売：国別
    • 中東, アフリカ ・ラテンアメリカの第三世代EGFR-TKI標的治療薬の収益：国別: 2018 VS 2022 VS 2029
    • 中東, アフリカ ・ラテンアメリカの第三世代EGFR-TKI標的治療薬の収益：国別 (2018-2029)
    • 中東, アフリカ ・ラテンアメリカの第三世代EGFR-TKI標的治療薬の販売：国別 (2018-2029)
    • ブラジル
    • メキシコ
    • トルコ
    • イスラエル
    • 湾岸協力理事会諸国

第11章 企業プロファイル

  • AstraZeneca
  • Hansoh Pharmaceuticak
  • Aisen Pharmaceutical
  • Nanjing Sanhome Pharmaceutical Co.Ltd.
  • Shanghai Allist Pharmaceuticals Co., Ltd.
  • Jiangsu Aosaikang Pharmaceutical
  • Suzhou NeuPharma Co., Ltd.
  • InventisBio Co., Ltd.
  • Betta Pharmaceuticals Co.Ltd
  • Jiangsu Maidu Drug Research and Development Co., Ltd.
  • Shanghai Saiyuan Biotechnology Co., Ltd.
  • EpimAb
  • Stellar Infinity Company Ltd.

第12章 業界チェーンと販売チャネルの分析

  • 第三世代EGFR-TKI標的治療薬 業界チェーン分析
  • 第三世代EGFR-TKI標的治療薬 主要原材料
    • 主要原材料
    • 原材料の主要サプライヤー
  • 第三世代EGFR-TKI標的治療薬 生産形態とプロセス
  • 第三世代EGFR-TKI標的治療薬 販売およびマーケティング
    • 第三世代EGFR-TKI標的治療薬 販売チャネルs
    • 第三世代EGFR-TKI標的治療薬 卸業者
  • 第三世代EGFR-TKI標的治療薬 顧客

第13章 市場動向

  • 第三世代EGFR-TKI標的治療薬 業界動向
  • 第三世代EGFR-TKI標的治療薬 市場の促進要因
  • 第三世代EGFR-TKI標的治療薬 市場の課題
  • 第三世代EGFR-TKI標的治療薬 市場の抑制要因

第14章 主な調査結果 世界の第三世代EGFR-TKI標的治療薬の主な市場調査結果

第15章 付録

図表

List of Tables

  • Table 1. Global Third Generation EGFR-TKI Targeted Therapy Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
  • Table 2. Major Manufacturers of Injection
  • Table 3. Major Manufacturers of Tablet
  • Table 4. Major Manufacturers of Otherss
  • Table 5. Global Third Generation EGFR-TKI Targeted Therapy Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
  • Table 6. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
  • Table 7. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Region (2018-2023) & (US$ Million)
  • Table 8. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Region (2024-2029) & (US$ Million)
  • Table 9. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Region (2018-2023)
  • Table 10. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Region (2024-2029)
  • Table 11. Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
  • Table 12. Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Region (2018-2023) & (K Units)
  • Table 13. Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Region (2024-2029) & (K Units)
  • Table 14. Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales Market Share by Region (2018-2023)
  • Table 15. Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales Market Share by Region (2024-2029)
  • Table 16. Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Manufacturers (2018-2023) & (K Units)
  • Table 17. Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales Share by Manufacturers (2018-2023)
  • Table 18. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Manufacturers (2018-2023) & (US$ Million)
  • Table 19. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Share by Manufacturers (2018-2023)
  • Table 20. Global Key Players of Third Generation EGFR-TKI Targeted Therapy Drugs, Industry Ranking, 2021 VS 2022 VS 2023
  • Table 21. Third Generation EGFR-TKI Targeted Therapy Drugs Price by Manufacturers 2018-2023 (US$/Unit)
  • Table 22. Global Third Generation EGFR-TKI Targeted Therapy Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 23. Global Third Generation EGFR-TKI Targeted Therapy Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Third Generation EGFR-TKI Targeted Therapy Drugs as of 2022)
  • Table 24. Global Key Manufacturers of Third Generation EGFR-TKI Targeted Therapy Drugs, Manufacturing Base Distribution and Headquarters
  • Table 25. Global Key Manufacturers of Third Generation EGFR-TKI Targeted Therapy Drugs, Product Offered and Application
  • Table 26. Global Key Manufacturers of Third Generation EGFR-TKI Targeted Therapy Drugs, Date of Enter into This Industry
  • Table 27. Mergers & Acquisitions, Expansion Plans
  • Table 28. Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Type (2018-2023) & (K Units)
  • Table 29. Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Type (2024-2029) & (K Units)
  • Table 30. Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales Share by Type (2018-2023)
  • Table 31. Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales Share by Type (2024-2029)
  • Table 32. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Type (2018-2023) & (US$ Million)
  • Table 33. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Type (2024-2029) & (US$ Million)
  • Table 34. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Share by Type (2018-2023)
  • Table 35. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Share by Type (2024-2029)
  • Table 36. Third Generation EGFR-TKI Targeted Therapy Drugs Price by Type (2018-2023) & (US$/Unit)
  • Table 37. Global Third Generation EGFR-TKI Targeted Therapy Drugs Price Forecast by Type (2024-2029) & (US$/Unit)
  • Table 38. Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Application (2018-2023) & (K Units)
  • Table 39. Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Application (2024-2029) & (K Units)
  • Table 40. Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales Share by Application (2018-2023)
  • Table 41. Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales Share by Application (2024-2029)
  • Table 42. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Application (2018-2023) & (US$ Million)
  • Table 43. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Application (2024-2029) & (US$ Million)
  • Table 44. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Share by Application (2018-2023)
  • Table 45. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Share by Application (2024-2029)
  • Table 46. Third Generation EGFR-TKI Targeted Therapy Drugs Price by Application (2018-2023) & (US$/Unit)
  • Table 47. Global Third Generation EGFR-TKI Targeted Therapy Drugs Price Forecast by Application (2024-2029) & (US$/Unit)
  • Table 48. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Type (2018-2023) & (K Units)
  • Table 49. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Type (2024-2029) & (K Units)
  • Table 50. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Type (2018-2023) & (US$ Million)
  • Table 51. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Type (2024-2029) & (US$ Million)
  • Table 52. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Application (2018-2023) & (K Units)
  • Table 53. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Application (2024-2029) & (K Units)
  • Table 54. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Application (2018-2023) & (US$ Million)
  • Table 55. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Application (2024-2029) & (US$ Million)
  • Table 56. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
  • Table 57. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Country (2018-2023) & (US$ Million)
  • Table 58. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Country (2024-2029) & (US$ Million)
  • Table 59. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Country (2018-2023) & (K Units)
  • Table 60. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Country (2024-2029) & (K Units)
  • Table 61. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Type (2018-2023) & (K Units)
  • Table 62. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Type (2024-2029) & (K Units)
  • Table 63. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Type (2018-2023) & (US$ Million)
  • Table 64. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Type (2024-2029) & (US$ Million)
  • Table 65. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Application (2018-2023) & (K Units)
  • Table 66. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Application (2024-2029) & (K Units)
  • Table 67. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Application (2018-2023) & (US$ Million)
  • Table 68. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Application (2024-2029) & (US$ Million)
  • Table 69. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
  • Table 70. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Country (2018-2023) & (US$ Million)
  • Table 71. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Country (2024-2029) & (US$ Million)
  • Table 72. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Country (2018-2023) & (K Units)
  • Table 73. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Country (2024-2029) & (K Units)
  • Table 74. China Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Type (2018-2023) & (K Units)
  • Table 75. China Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Type (2024-2029) & (K Units)
  • Table 76. China Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Type (2018-2023) & (US$ Million)
  • Table 77. China Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Type (2024-2029) & (US$ Million)
  • Table 78. China Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Application (2018-2023) & (K Units)
  • Table 79. China Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Application (2024-2029) & (K Units)
  • Table 80. China Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Application (2018-2023) & (US$ Million)
  • Table 81. China Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Application (2024-2029) & (US$ Million)
  • Table 82. Asia Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Type (2018-2023) & (K Units)
  • Table 83. Asia Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Type (2024-2029) & (K Units)
  • Table 84. Asia Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Type (2018-2023) & (US$ Million)
  • Table 85. Asia Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Type (2024-2029) & (US$ Million)
  • Table 86. Asia Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Application (2018-2023) & (K Units)
  • Table 87. Asia Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Application (2024-2029) & (K Units)
  • Table 88. Asia Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Application (2018-2023) & (US$ Million)
  • Table 89. Asia Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Application (2024-2029) & (US$ Million)
  • Table 90. Asia Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
  • Table 91. Asia Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Region (2018-2023) & (US$ Million)
  • Table 92. Asia Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Region (2024-2029) & (US$ Million)
  • Table 93. Asia Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Region (2018-2023) & (K Units)
  • Table 94. Asia Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Region (2024-2029) & (K Units)
  • Table 95. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Type (2018-2023) & (K Units)
  • Table 96. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Type (2024-2029) & (K Units)
  • Table 97. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Type (2018-2023) & (US$ Million)
  • Table 98. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Type (2024-2029) & (US$ Million)
  • Table 99. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Application (2018-2023) & (K Units)
  • Table 100. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Application (2024-2029) & (K Units)
  • Table 101. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Application (2018-2023) & (US$ Million)
  • Table 102. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Application (2024-2029) & (US$ Million)
  • Table 103. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
  • Table 104. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Country (2018-2023) & (US$ Million)
  • Table 105. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Country (2024-2029) & (US$ Million)
  • Table 106. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Country (2018-2023) & (K Units)
  • Table 107. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Country (2024-2029) & (K Units)
  • Table 108. AstraZeneca Company Information
  • Table 109. AstraZeneca Description and Major Businesses
  • Table 110. AstraZeneca Third Generation EGFR-TKI Targeted Therapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
  • Table 111. AstraZeneca Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 112. AstraZeneca Recent Developments
  • Table 113. Hansoh Pharmaceuticak Company Information
  • Table 114. Hansoh Pharmaceuticak Description and Major Businesses
  • Table 115. Hansoh Pharmaceuticak Third Generation EGFR-TKI Targeted Therapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
  • Table 116. Hansoh Pharmaceuticak Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 117. Hansoh Pharmaceuticak Recent Developments
  • Table 118. Aisen Pharmaceutical Company Information
  • Table 119. Aisen Pharmaceutical Description and Major Businesses
  • Table 120. Aisen Pharmaceutical Third Generation EGFR-TKI Targeted Therapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
  • Table 121. Aisen Pharmaceutical Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 122. Aisen Pharmaceutical Recent Developments
  • Table 123. Nanjing Sanhome Pharmaceutical Co.Ltd. Company Information
  • Table 124. Nanjing Sanhome Pharmaceutical Co.Ltd. Description and Major Businesses
  • Table 125. Nanjing Sanhome Pharmaceutical Co.Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
  • Table 126. Nanjing Sanhome Pharmaceutical Co.Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 127. Nanjing Sanhome Pharmaceutical Co.Ltd. Recent Developments
  • Table 128. Shanghai Allist Pharmaceuticals Co., Ltd. Company Information
  • Table 129. Shanghai Allist Pharmaceuticals Co., Ltd. Description and Major Businesses
  • Table 130. Shanghai Allist Pharmaceuticals Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
  • Table 131. Shanghai Allist Pharmaceuticals Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 132. Shanghai Allist Pharmaceuticals Co., Ltd. Recent Developments
  • Table 133. Jiangsu Aosaikang Pharmaceutical Company Information
  • Table 134. Jiangsu Aosaikang Pharmaceutical Description and Major Businesses
  • Table 135. Jiangsu Aosaikang Pharmaceutical Third Generation EGFR-TKI Targeted Therapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
  • Table 136. Jiangsu Aosaikang Pharmaceutical Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 137. Jiangsu Aosaikang Pharmaceutical Recent Developments
  • Table 138. Suzhou NeuPharma Co., Ltd. Company Information
  • Table 139. Suzhou NeuPharma Co., Ltd. Description and Major Businesses
  • Table 140. Suzhou NeuPharma Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
  • Table 141. Suzhou NeuPharma Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 142. Suzhou NeuPharma Co., Ltd. Recent Developments
  • Table 143. InventisBio Co., Ltd. Company Information
  • Table 144. InventisBio Co., Ltd. Description and Major Businesses
  • Table 145. InventisBio Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
  • Table 146. InventisBio Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 147. InventisBio Co., Ltd. Recent Developments
  • Table 148. Betta Pharmaceuticals Co.Ltd Company Information
  • Table 149. Betta Pharmaceuticals Co.Ltd Description and Major Businesses
  • Table 150. Betta Pharmaceuticals Co.Ltd Third Generation EGFR-TKI Targeted Therapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
  • Table 151. Betta Pharmaceuticals Co.Ltd Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 152. Betta Pharmaceuticals Co.Ltd Recent Developments
  • Table 153. Jiangsu Maidu Drug Research and Development Co., Ltd. Company Information
  • Table 154. Jiangsu Maidu Drug Research and Development Co., Ltd. Description and Major Businesses
  • Table 155. Jiangsu Maidu Drug Research and Development Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
  • Table 156. Jiangsu Maidu Drug Research and Development Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 157. Jiangsu Maidu Drug Research and Development Co., Ltd. Recent Developments
  • Table 158. Shanghai Saiyuan Biotechnology Co., Ltd. Company Information
  • Table 159. Shanghai Saiyuan Biotechnology Co., Ltd. Description and Major Businesses
  • Table 160. Shanghai Saiyuan Biotechnology Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
  • Table 161. Shanghai Saiyuan Biotechnology Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 162. Shanghai Saiyuan Biotechnology Co., Ltd. Recent Developments
  • Table 163. EpimAb Company Information
  • Table 164. EpimAb Description and Major Businesses
  • Table 165. EpimAb Third Generation EGFR-TKI Targeted Therapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
  • Table 166. EpimAb Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 167. EpimAb Recent Developments
  • Table 168. Stellar Infinity Company Ltd. Company Information
  • Table 169. Stellar Infinity Company Ltd. Description and Major Businesses
  • Table 170. Stellar Infinity Company Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
  • Table 171. Stellar Infinity Company Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 172. Stellar Infinity Company Ltd. Recent Developments
  • Table 173. Key Raw Materials Lists
  • Table 174. Raw Materials Key Suppliers Lists
  • Table 175. Third Generation EGFR-TKI Targeted Therapy Drugs Distributors List
  • Table 176. Third Generation EGFR-TKI Targeted Therapy Drugs Customers List
  • Table 177. Third Generation EGFR-TKI Targeted Therapy Drugs Market Trends
  • Table 178. Third Generation EGFR-TKI Targeted Therapy Drugs Market Drivers
  • Table 179. Third Generation EGFR-TKI Targeted Therapy Drugs Market Challenges
  • Table 180. Third Generation EGFR-TKI Targeted Therapy Drugs Market Restraints
  • Table 181. Research Programs/Design for This Report
  • Table 182. Key Data Information from Secondary Sources
  • Table 183. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Third Generation EGFR-TKI Targeted Therapy Drugs Product Picture
  • Figure 2. Global Third Generation EGFR-TKI Targeted Therapy Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
  • Figure 3. Global Third Generation EGFR-TKI Targeted Therapy Drugs Market Share by Type in 2022 & 2029
  • Figure 4. Injection Product Picture
  • Figure 5. Tablet Product Picture
  • Figure 6. Otherss Product Picture
  • Figure 7. Global Third Generation EGFR-TKI Targeted Therapy Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
  • Figure 8. Global Third Generation EGFR-TKI Targeted Therapy Drugs Market Share by Application in 2022 & 2029
  • Figure 9. Lung Cancer Treatment
  • Figure 10. Clinical Research
  • Figure 11. Otherss
  • Figure 12. Third Generation EGFR-TKI Targeted Therapy Drugs Report Years Considered
  • Figure 13. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2029
  • Figure 14. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue 2018-2029 (US$ Million)
  • Figure 15. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Region in Percentage: 2022 Versus 2029
  • Figure 16. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Region (2018-2029)
  • Figure 17. Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales 2018-2029 ((K Units)
  • Figure 18. Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales Market Share by Region (2018-2029)
  • Figure 19. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Sales YoY (2018-2029) & (K Units)
  • Figure 20. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Revenue YoY (2018-2029) & (US$ Million)
  • Figure 21. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Sales YoY (2018-2029) & (K Units)
  • Figure 22. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Revenue YoY (2018-2029) & (US$ Million)
  • Figure 23. China Third Generation EGFR-TKI Targeted Therapy Drugs Sales YoY (2018-2029) & (K Units)
  • Figure 24. China Third Generation EGFR-TKI Targeted Therapy Drugs Revenue YoY (2018-2029) & (US$ Million)
  • Figure 25. Asia (excluding China) Third Generation EGFR-TKI Targeted Therapy Drugs Sales YoY (2018-2029) & (K Units)
  • Figure 26. Asia (excluding China) Third Generation EGFR-TKI Targeted Therapy Drugs Revenue YoY (2018-2029) & (US$ Million)
  • Figure 27. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Sales YoY (2018-2029) & (K Units)
  • Figure 28. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Revenue YoY (2018-2029) & (US$ Million)
  • Figure 29. The Third Generation EGFR-TKI Targeted Therapy Drugs Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
  • Figure 30. The Top 5 and 10 Largest Manufacturers of Third Generation EGFR-TKI Targeted Therapy Drugs in the World: Market Share by Third Generation EGFR-TKI Targeted Therapy Drugs Revenue in 2022
  • Figure 31. Global Third Generation EGFR-TKI Targeted Therapy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
  • Figure 32. Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales Market Share by Type (2018-2029)
  • Figure 33. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Type (2018-2029)
  • Figure 34. Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales Market Share by Application (2018-2029)
  • Figure 35. Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Application (2018-2029)
  • Figure 36. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Sales Market Share by Type (2018-2029)
  • Figure 37. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Type (2018-2029)
  • Figure 38. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Sales Market Share by Application (2018-2029)
  • Figure 39. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Application (2018-2029)
  • Figure 40. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Share by Country (2018-2029)
  • Figure 41. US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Sales Share by Country (2018-2029)
  • Figure 42. U.S. Third Generation EGFR-TKI Targeted Therapy Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 43. Canada Third Generation EGFR-TKI Targeted Therapy Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 44. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Sales Market Share by Type (2018-2029)
  • Figure 45. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Type (2018-2029)
  • Figure 46. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Sales Market Share by Application (2018-2029)
  • Figure 47. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Application (2018-2029)
  • Figure 48. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Share by Country (2018-2029)
  • Figure 49. Europe Third Generation EGFR-TKI Targeted Therapy Drugs Sales Share by Country (2018-2029)
  • Figure 50. Germany Third Generation EGFR-TKI Targeted Therapy Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 51. France Third Generation EGFR-TKI Targeted Therapy Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 52. U.K. Third Generation EGFR-TKI Targeted Therapy Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 53. Italy Third Generation EGFR-TKI Targeted Therapy Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 54. Russia Third Generation EGFR-TKI Targeted Therapy Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 55. China Third Generation EGFR-TKI Targeted Therapy Drugs Sales Market Share by Type (2018-2029)
  • Figure 56. China Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Type (2018-2029)
  • Figure 57. China Third Generation EGFR-TKI Targeted Therapy Drugs Sales Market Share by Application (2018-2029)
  • Figure 58. China Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Application (2018-2029)
  • Figure 59. Asia Third Generation EGFR-TKI Targeted Therapy Drugs Sales Market Share by Type (2018-2029)
  • Figure 60. Asia Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Type (2018-2029)
  • Figure 61. Asia Third Generation EGFR-TKI Targeted Therapy Drugs Sales Market Share by Application (2018-2029)
  • Figure 62. Asia Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Application (2018-2029)
  • Figure 63. Asia Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Share by Region (2018-2029)
  • Figure 64. Asia Third Generation EGFR-TKI Targeted Therapy Drugs Sales Share by Region (2018-2029)
  • Figure 65. Japan Third Generation EGFR-TKI Targeted Therapy Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 66. South Korea Third Generation EGFR-TKI Targeted Therapy Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 67. China Taiwan Third Generation EGFR-TKI Targeted Therapy Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 68. Southeast Asia Third Generation EGFR-TKI Targeted Therapy Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 69. India Third Generation EGFR-TKI Targeted Therapy Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 70. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Sales Market Share by Type (2018-2029)
  • Figure 71. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Type (2018-2029)
  • Figure 72. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Sales Market Share by Application (2018-2029)
  • Figure 73. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Application (2018-2029)
  • Figure 74. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Share by Country (2018-2029)
  • Figure 75. Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Sales Share by Country (2018-2029)
  • Figure 76. Brazil Third Generation EGFR-TKI Targeted Therapy Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 77. Mexico Third Generation EGFR-TKI Targeted Therapy Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 78. Turkey Third Generation EGFR-TKI Targeted Therapy Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 79. Israel Third Generation EGFR-TKI Targeted Therapy Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 80. GCC Countries Third Generation EGFR-TKI Targeted Therapy Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 81. Third Generation EGFR-TKI Targeted Therapy Drugs Value Chain
  • Figure 82. Third Generation EGFR-TKI Targeted Therapy Drugs Production Process
  • Figure 83. Channels of Distribution
  • Figure 84. Distributors Profiles
  • Figure 85. Bottom-up and Top-down Approaches for This Report
  • Figure 86. Data Triangulation
  • Figure 87. Key Executives Interviewed
目次

This research report focuses on the Third Generation EGFR-TKI Targeted Therapy Drugs Market. It analyzes market size, trends and demand forecasts, as well as growth factors and challenges. The report provides market data breakdowns by type, application, company, and region, in addition to competitive landscape and key company profiles.

TABLE OF CONTENTS

1 Study Coverage

  • 1.1 Third Generation EGFR-TKI Targeted Therapy Drugs Product Introduction
  • 1.2 Market by Type
    • 1.2.1 Global Third Generation EGFR-TKI Targeted Therapy Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
    • 1.2.2 Injection
    • 1.2.3 Tablet
    • 1.2.4 Otherss
  • 1.3 Market by Application
    • 1.3.1 Global Third Generation EGFR-TKI Targeted Therapy Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
    • 1.3.2 Lung Cancer Treatment
    • 1.3.3 Clinical Research
    • 1.3.4 Otherss
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Executive Summary

  • 2.1 Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales Estimates and Forecasts 2018-2029
  • 2.2 Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Region
    • 2.2.1 Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Region: 2018 VS 2022 VS 2029
    • 2.2.2 Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Region (2018-2023)
    • 2.2.3 Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Region (2024-2029)
    • 2.2.4 Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Region (2018-2029)
  • 2.3 Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales Estimates and Forecasts 2018-2029
  • 2.4 Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Region
    • 2.4.1 Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Region: 2018 VS 2022 VS 2029
    • 2.4.2 Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Region (2018-2023)
    • 2.4.3 Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Region (2024-2029)
    • 2.4.4 Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales Market Share by Region (2018-2029)
  • 2.5 US & Canada
  • 2.6 Europe
  • 2.7 China
  • 2.8 Asia (excluding China)
  • 2.9 Middle East, Africa and Latin America

3 Competition by Manufactures

  • 3.1 Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Manufacturers
    • 3.1.1 Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Manufacturers (2018-2023)
    • 3.1.2 Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales Market Share by Manufacturers (2018-2023)
    • 3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Third Generation EGFR-TKI Targeted Therapy Drugs in 2022
  • 3.2 Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Manufacturers
    • 3.2.1 Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Manufacturers (2018-2023)
    • 3.2.2 Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Manufacturers (2018-2023)
    • 3.2.3 Global Top 10 and Top 5 Companies by Third Generation EGFR-TKI Targeted Therapy Drugs Revenue in 2022
  • 3.3 Global Key Players of Third Generation EGFR-TKI Targeted Therapy Drugs, Industry Ranking, 2021 VS 2022 VS 2023
  • 3.4 Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales Price by Manufacturers
  • 3.5 Analysis of Competitive Landscape
    • 3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
    • 3.5.2 Global Third Generation EGFR-TKI Targeted Therapy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
  • 3.6 Global Key Manufacturers of Third Generation EGFR-TKI Targeted Therapy Drugs, Manufacturing Base Distribution and Headquarters
  • 3.7 Global Key Manufacturers of Third Generation EGFR-TKI Targeted Therapy Drugs, Product Offered and Application
  • 3.8 Global Key Manufacturers of Third Generation EGFR-TKI Targeted Therapy Drugs, Date of Enter into This Industry
  • 3.9 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

  • 4.1 Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Type
    • 4.1.1 Global Third Generation EGFR-TKI Targeted Therapy Drugs Historical Sales by Type (2018-2023)
    • 4.1.2 Global Third Generation EGFR-TKI Targeted Therapy Drugs Forecasted Sales by Type (2024-2029)
    • 4.1.3 Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales Market Share by Type (2018-2029)
  • 4.2 Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Type
    • 4.2.1 Global Third Generation EGFR-TKI Targeted Therapy Drugs Historical Revenue by Type (2018-2023)
    • 4.2.2 Global Third Generation EGFR-TKI Targeted Therapy Drugs Forecasted Revenue by Type (2024-2029)
    • 4.2.3 Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Type (2018-2029)
  • 4.3 Global Third Generation EGFR-TKI Targeted Therapy Drugs Price by Type
    • 4.3.1 Global Third Generation EGFR-TKI Targeted Therapy Drugs Price by Type (2018-2023)
    • 4.3.2 Global Third Generation EGFR-TKI Targeted Therapy Drugs Price Forecast by Type (2024-2029)

5 Market Size by Application

  • 5.1 Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Application
    • 5.1.1 Global Third Generation EGFR-TKI Targeted Therapy Drugs Historical Sales by Application (2018-2023)
    • 5.1.2 Global Third Generation EGFR-TKI Targeted Therapy Drugs Forecasted Sales by Application (2024-2029)
    • 5.1.3 Global Third Generation EGFR-TKI Targeted Therapy Drugs Sales Market Share by Application (2018-2029)
  • 5.2 Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Application
    • 5.2.1 Global Third Generation EGFR-TKI Targeted Therapy Drugs Historical Revenue by Application (2018-2023)
    • 5.2.2 Global Third Generation EGFR-TKI Targeted Therapy Drugs Forecasted Revenue by Application (2024-2029)
    • 5.2.3 Global Third Generation EGFR-TKI Targeted Therapy Drugs Revenue Market Share by Application (2018-2029)
  • 5.3 Global Third Generation EGFR-TKI Targeted Therapy Drugs Price by Application
    • 5.3.1 Global Third Generation EGFR-TKI Targeted Therapy Drugs Price by Application (2018-2023)
    • 5.3.2 Global Third Generation EGFR-TKI Targeted Therapy Drugs Price Forecast by Application (2024-2029)

6 US & Canada

  • 6.1 US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Market Size by Type
    • 6.1.1 US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Type (2018-2029)
    • 6.1.2 US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Type (2018-2029)
  • 6.2 US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Market Size by Application
    • 6.2.1 US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Application (2018-2029)
    • 6.2.2 US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Application (2018-2029)
  • 6.3 US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Market Size by Country
    • 6.3.1 US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Country: 2018 VS 2022 VS 2029
    • 6.3.2 US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Country (2018-2029)
    • 6.3.3 US & Canada Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Country (2018-2029)
    • 6.3.4 US
    • 6.3.5 Canada

7 Europe

  • 7.1 Europe Third Generation EGFR-TKI Targeted Therapy Drugs Market Size by Type
    • 7.1.1 Europe Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Type (2018-2029)
    • 7.1.2 Europe Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Type (2018-2029)
  • 7.2 Europe Third Generation EGFR-TKI Targeted Therapy Drugs Market Size by Application
    • 7.2.1 Europe Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Application (2018-2029)
    • 7.2.2 Europe Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Application (2018-2029)
  • 7.3 Europe Third Generation EGFR-TKI Targeted Therapy Drugs Market Size by Country
    • 7.3.1 Europe Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Country: 2018 VS 2022 VS 2029
    • 7.3.2 Europe Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Country (2018-2029)
    • 7.3.3 Europe Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Country (2018-2029)
    • 7.3.4 Germany
    • 7.3.5 France
    • 7.3.6 U.K.
    • 7.3.7 Italy
    • 7.3.8 Russia

8 China

  • 8.1 China Third Generation EGFR-TKI Targeted Therapy Drugs Market Size
    • 8.1.1 China Third Generation EGFR-TKI Targeted Therapy Drugs Sales (2018-2029)
    • 8.1.2 China Third Generation EGFR-TKI Targeted Therapy Drugs Revenue (2018-2029)
  • 8.2 China Third Generation EGFR-TKI Targeted Therapy Drugs Market Size by Application
    • 8.2.1 China Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Application (2018-2029)
    • 8.2.2 China Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Application (2018-2029)

9 Asia (excluding China)

  • 9.1 Asia Third Generation EGFR-TKI Targeted Therapy Drugs Market Size by Type
    • 9.1.1 Asia Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Type (2018-2029)
    • 9.1.2 Asia Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Type (2018-2029)
  • 9.2 Asia Third Generation EGFR-TKI Targeted Therapy Drugs Market Size by Application
    • 9.2.1 Asia Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Application (2018-2029)
    • 9.2.2 Asia Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Application (2018-2029)
  • 9.3 Asia Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Region
    • 9.3.1 Asia Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Region: 2018 VS 2022 VS 2029
    • 9.3.2 Asia Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Region (2018-2029)
    • 9.3.3 Asia Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Region (2018-2029)
    • 9.3.4 Japan
    • 9.3.5 South Korea
    • 9.3.6 China Taiwan
    • 9.3.7 Southeast Asia
    • 9.3.8 India

10 Middle East, Africa and Latin America

  • 10.1 Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Market Size by Type
    • 10.1.1 Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Type (2018-2029)
    • 10.1.2 Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Type (2018-2029)
  • 10.2 Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Market Size by Application
    • 10.2.1 Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Application (2018-2029)
    • 10.2.2 Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Application (2018-2029)
  • 10.3 Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Country
    • 10.3.1 Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Country: 2018 VS 2022 VS 2029
    • 10.3.2 Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Revenue by Country (2018-2029)
    • 10.3.3 Middle East, Africa and Latin America Third Generation EGFR-TKI Targeted Therapy Drugs Sales by Country (2018-2029)
    • 10.3.4 Brazil
    • 10.3.5 Mexico
    • 10.3.6 Turkey
    • 10.3.7 Israel
    • 10.3.8 GCC Countries

11 Company Profiles

  • 11.1 AstraZeneca
    • 11.1.1 AstraZeneca Company Information
    • 11.1.2 AstraZeneca Overview
    • 11.1.3 AstraZeneca Third Generation EGFR-TKI Targeted Therapy Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.1.4 AstraZeneca Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.1.5 AstraZeneca Recent Developments
  • 11.2 Hansoh Pharmaceuticak
    • 11.2.1 Hansoh Pharmaceuticak Company Information
    • 11.2.2 Hansoh Pharmaceuticak Overview
    • 11.2.3 Hansoh Pharmaceuticak Third Generation EGFR-TKI Targeted Therapy Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.2.4 Hansoh Pharmaceuticak Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.2.5 Hansoh Pharmaceuticak Recent Developments
  • 11.3 Aisen Pharmaceutical
    • 11.3.1 Aisen Pharmaceutical Company Information
    • 11.3.2 Aisen Pharmaceutical Overview
    • 11.3.3 Aisen Pharmaceutical Third Generation EGFR-TKI Targeted Therapy Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.3.4 Aisen Pharmaceutical Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.3.5 Aisen Pharmaceutical Recent Developments
  • 11.4 Nanjing Sanhome Pharmaceutical Co.Ltd.
    • 11.4.1 Nanjing Sanhome Pharmaceutical Co.Ltd. Company Information
    • 11.4.2 Nanjing Sanhome Pharmaceutical Co.Ltd. Overview
    • 11.4.3 Nanjing Sanhome Pharmaceutical Co.Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.4.4 Nanjing Sanhome Pharmaceutical Co.Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.4.5 Nanjing Sanhome Pharmaceutical Co.Ltd. Recent Developments
  • 11.5 Shanghai Allist Pharmaceuticals Co., Ltd.
    • 11.5.1 Shanghai Allist Pharmaceuticals Co., Ltd. Company Information
    • 11.5.2 Shanghai Allist Pharmaceuticals Co., Ltd. Overview
    • 11.5.3 Shanghai Allist Pharmaceuticals Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.5.4 Shanghai Allist Pharmaceuticals Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.5.5 Shanghai Allist Pharmaceuticals Co., Ltd. Recent Developments
  • 11.6 Jiangsu Aosaikang Pharmaceutical
    • 11.6.1 Jiangsu Aosaikang Pharmaceutical Company Information
    • 11.6.2 Jiangsu Aosaikang Pharmaceutical Overview
    • 11.6.3 Jiangsu Aosaikang Pharmaceutical Third Generation EGFR-TKI Targeted Therapy Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.6.4 Jiangsu Aosaikang Pharmaceutical Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.6.5 Jiangsu Aosaikang Pharmaceutical Recent Developments
  • 11.7 Suzhou NeuPharma Co., Ltd.
    • 11.7.1 Suzhou NeuPharma Co., Ltd. Company Information
    • 11.7.2 Suzhou NeuPharma Co., Ltd. Overview
    • 11.7.3 Suzhou NeuPharma Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.7.4 Suzhou NeuPharma Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.7.5 Suzhou NeuPharma Co., Ltd. Recent Developments
  • 11.8 InventisBio Co., Ltd.
    • 11.8.1 InventisBio Co., Ltd. Company Information
    • 11.8.2 InventisBio Co., Ltd. Overview
    • 11.8.3 InventisBio Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.8.4 InventisBio Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.8.5 InventisBio Co., Ltd. Recent Developments
  • 11.9 Betta Pharmaceuticals Co.Ltd
    • 11.9.1 Betta Pharmaceuticals Co.Ltd Company Information
    • 11.9.2 Betta Pharmaceuticals Co.Ltd Overview
    • 11.9.3 Betta Pharmaceuticals Co.Ltd Third Generation EGFR-TKI Targeted Therapy Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.9.4 Betta Pharmaceuticals Co.Ltd Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.9.5 Betta Pharmaceuticals Co.Ltd Recent Developments
  • 11.10 Jiangsu Maidu Drug Research and Development Co., Ltd.
    • 11.10.1 Jiangsu Maidu Drug Research and Development Co., Ltd. Company Information
    • 11.10.2 Jiangsu Maidu Drug Research and Development Co., Ltd. Overview
    • 11.10.3 Jiangsu Maidu Drug Research and Development Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.10.4 Jiangsu Maidu Drug Research and Development Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.10.5 Jiangsu Maidu Drug Research and Development Co., Ltd. Recent Developments
  • 11.11 Shanghai Saiyuan Biotechnology Co., Ltd.
    • 11.11.1 Shanghai Saiyuan Biotechnology Co., Ltd. Company Information
    • 11.11.2 Shanghai Saiyuan Biotechnology Co., Ltd. Overview
    • 11.11.3 Shanghai Saiyuan Biotechnology Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.11.4 Shanghai Saiyuan Biotechnology Co., Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.11.5 Shanghai Saiyuan Biotechnology Co., Ltd. Recent Developments
  • 11.12 EpimAb
    • 11.12.1 EpimAb Company Information
    • 11.12.2 EpimAb Overview
    • 11.12.3 EpimAb Third Generation EGFR-TKI Targeted Therapy Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.12.4 EpimAb Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.12.5 EpimAb Recent Developments
  • 11.13 Stellar Infinity Company Ltd.
    • 11.13.1 Stellar Infinity Company Ltd. Company Information
    • 11.13.2 Stellar Infinity Company Ltd. Overview
    • 11.13.3 Stellar Infinity Company Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.13.4 Stellar Infinity Company Ltd. Third Generation EGFR-TKI Targeted Therapy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.13.5 Stellar Infinity Company Ltd. Recent Developments

12 Industry Chain and Sales Channels Analysis

  • 12.1 Third Generation EGFR-TKI Targeted Therapy Drugs Industry Chain Analysis
  • 12.2 Third Generation EGFR-TKI Targeted Therapy Drugs Key Raw Materials
    • 12.2.1 Key Raw Materials
    • 12.2.2 Raw Materials Key Suppliers
  • 12.3 Third Generation EGFR-TKI Targeted Therapy Drugs Production Mode & Process
  • 12.4 Third Generation EGFR-TKI Targeted Therapy Drugs Sales and Marketing
    • 12.4.1 Third Generation EGFR-TKI Targeted Therapy Drugs Sales Channels
    • 12.4.2 Third Generation EGFR-TKI Targeted Therapy Drugs Distributors
  • 12.5 Third Generation EGFR-TKI Targeted Therapy Drugs Customers

13 Market Dynamics

  • 13.1 Third Generation EGFR-TKI Targeted Therapy Drugs Industry Trends
  • 13.2 Third Generation EGFR-TKI Targeted Therapy Drugs Market Drivers
  • 13.3 Third Generation EGFR-TKI Targeted Therapy Drugs Market Challenges
  • 13.4 Third Generation EGFR-TKI Targeted Therapy Drugs Market Restraints

14 Key Findings in The Global Third Generation EGFR-TKI Targeted Therapy Drugs Study

15 Appendix

  • 15.1 Research Methodology
    • 15.1.1 Methodology/Research Approach
    • 15.1.2 Data Source
  • 15.2 Author Details
  • 15.3 Disclaimer